Perjeta®

Active substance

Pertuzumab

Holder

Roche

Status

Closed

Indication

in combination with Herceptin® (trastuzumab) and chemotherapy for the adjuvant treatment of adult patients with HER2 positive early breast cancer at high risk of recurrence defined as lymph node positive disease

Public documents

Approbation

Information for the patient

Informed consent

Last update

09/07/2019

Last updated on 13/02/2024